THE FUTURE, - Solvay

209808 209815 209821
TAKING DRUG SYNTHESIS TO THE NEXT
LEVEL: FROM BATCH TO FLOW PROCESSES
From chemical to technical
THE PROJECT. During drug discovery and
development processes, new compounds are
synthesized and tested for biological activity.
We are implementing a paradigm shift in the way
our compounds are being synthesized. This
paradigm shift concerns the move from batch
synthesis to continuous fl ow synthesis. In
continuous fl ow the various components of a
chemical reaction are continuously fed into micro
and milli reactor channels. These channels allow
for perfect heat and mass exchange compared to
a typical batch reactor. As a result we can follow
the optimal synthesis route with the safety of the
reaction under constant control. In addition,
a reduction of by-products plus a higher purity of
the main product can be achieved.
The application of this technology fundamentally
changes the development effort for scaling-up: it
no longer focuses on the reaction itself and
scaling-up becomes a technical, rather than a
chemical process. Operational responsiveness
increases dramatically.
PHARMACEUTICALS SECTOR
> Bart Vansteen ; Niek Buizer ; Fabrice Guillier ;
Peter Hoeijmakers ; Chris Kruse ; Gert Lagerweij ;
Bastiaan Lastdrager ; Carla Schenk ; Uwe Schoen ;
Leo Sliedregt.
RUSSIAN RAMP-UP: SOLVAY
PHARMACEUTICALS EXTENDS ITS
FOOTPRINT INTO POST-COMMUNIST RUSSIA
AND ACHIEVES EXCELLENT MARKET SHARE
A Russian success story
THE PROJECT. We started development
in Russia in 1998-1999: with a small offi ce in
Moscow and ten people hired locally, turnover
in 1999 was EUR one million. With 140 million
people spread over 11 time zones, we needed a
new sales team distributed over a wide area and
distant from the head offi ce. We selected young,
inexperienced people straight out of university,
mostly with medical training, and we trained them
in our in-house training centre. Using advanced
electronic fi eld support systems we gave them
positive feedback and liberally praise, we taught
them to strive to be champions and to reach for
the sky. With a turnover of EUR 150 million in
2008, we had a market share of 2.4%, and we
have now entered the top 10 companies
operating on the Russian pharmaceutical market.
A replicable success story?
PHARMACEUTICALS SECTOR
> Leonid Parshenkov.
MANUFACTURING AND SUPPLY
REPOSITIONING ITS SITES
Objective: excellence
THE PROJECT. We changed our business
model from plant centered to an integrated supply
chain model with centers of excellence. We added
an integrated supply chain based on the PULL
principle and we created an innovative, new
Central Demand and Supply Planning department.
This has increased our fl exibility to respond more
quickly to changes in the marketplace. All aspects
of the change management process (the
organization, performance oriented management
tools and training and development of our
employees) were addressed in our focus to
become an organization of world class excellence
driven by continuous improvement and with
positive fi nancial impact on cost and working
capital.
PHARMACEUTICALS SECTOR
> Ulf Suerig; Philippe Castellino; Daniel Graf;
Chantal Heroux; Jean-François Hilaire; Marc Lam;
Jean-Pierre Meriaux; Thomas Petit; Paul Robben;
Philippe Sail; Ton Stam.
Solvay Solvay live live - JUILLET - JULY 2009 - 35